Preserving an Incentive for Global Health R&D

  title={Preserving an Incentive for Global Health R\&D},
  author={Andrew S Robertson},
  journal={American Journal of Law \& Medicine},
  pages={524 - 542}
In December 2014, the United States government expanded the Priority Review Voucher (“PRV” or “voucher”) program to include Ebola and other related Filoviruses. By doing so, lawmakers provided a potentially powerful incentive for drug companies to invest time and money in the development of novel medicines for terrifying diseases. This expansion is one of several additions made to the PRV programs since 2012. Many companies rely on voucher resale to recoup research and development (“R&D”) costs…